Yang Woo Young, Park Hee Sun, Kim Young Jun, Yu Mi Hye, Jung Sung Il, Jeon Hae Jeong
Department of Radiology, Konkuk University School of Medicine, 120-1, Neungdong-ro, Gwangjin-gu, Seoul, 05030, Korea.
J Clin Ultrasound. 2017 Nov 12;45(9):542-550. doi: 10.1002/jcu.22499. Epub 2017 May 26.
To investigate the agreement between Kupffer phase of Sonazoid contrast-enhanced sonography (CEUS) and hepatobiliary phase of gadoxetic acid-enhanced MRI in the evaluation of focal liver lesions (FLLs).
One hundred fifty-four FLLs in 154 patients who underwent both Sonazoid CEUS and gadoxetic acid-enhanced liver MRI were included in this retrospective study. FLL visibility on the Kupffer-phase images was graded as one (invisible or isoenhancing), two (vaguely visible or vaguely hypoenhancing), or three (clearly visible or clearly hypoenhancing), and that on the hepatobiliary-phase images of MRI was graded as one (invisible or hyper/isointense), two (vaguely visible or weakly hypointense), or three (clearly visible or strongly hypointense). Pairwise comparison of lesion visibility between the two modalities was performed, and intermodality agreement was assessed.
On Kupffer-phase CEUS, 31 (20.1%) lesions were invisible, 17 (11.1%) were vaguely visible, and 106 (68.9%) were clearly visible. On the hepatobiliary-phase MRI, 9 (5.9%) lesions were invisible, 45 (29.2%) were vaguely visible, and 100 (64.9%) were clearly visible. Overall, lesion visibility scores were not significantly different between the two modalities (p = 0.121), but the visibility was significantly better on MRI in smaller lesions. Twenty-eight lesions (18.2%) showed discrepancy in the visibility on CEUS and MRI, and most of the cases (89.7%) were lesions that were invisible on CEUS but visible on MRI.
The overall visibility of FLLs was comparable between the Kupffer phase of Sonazoid-CEUS and the hepatobiliary-phase images of gadoxetic acid-enhanced MRI, with a discrepancy between the two modalities in 18% of the cases. © 2017 Wiley Periodicals, Inc. J Clin Ultrasound 45:542-550, 2017.
探讨索纳造影剂增强超声(CEUS)的库普弗期与钆塞酸增强MRI的肝胆期在评估肝脏局灶性病变(FLLs)方面的一致性。
本回顾性研究纳入了154例接受索纳造影剂CEUS和钆塞酸增强肝脏MRI检查的患者的154个FLLs。库普弗期图像上FLL的可视性分为1级(不可见或等增强)、2级(隐约可见或隐约低增强)或3级(清晰可见或清晰低增强),MRI肝胆期图像上的可视性分为1级(不可见或高/等信号)、2级(隐约可见或弱低信号)或3级(清晰可见或强低信号)。对两种检查方式下病变可视性进行两两比较,并评估不同检查方式之间的一致性。
在库普弗期CEUS上,31个(20.1%)病变不可见,17个(11.1%)隐约可见,106个(68.9%)清晰可见。在肝胆期MRI上,9个(5.9%)病变不可见,45个(29.2%)隐约可见,100个(64.9%)清晰可见。总体而言,两种检查方式下病变可视性评分无显著差异(p = 0.121),但在较小病变中,MRI的可视性明显更好。28个病变(18.2%)在CEUS和MRI上的可视性存在差异,大多数病例(89.7%)是在CEUS上不可见但在MRI上可见的病变。
索纳造影剂CEUS的库普弗期与钆塞酸增强MRI的肝胆期图像上FLL的总体可视性相当,18%的病例中两种检查方式存在差异。©2017威利期刊公司。《临床超声杂志》2017年第45卷:542 - 550页。